TABLE 3.

Evolution of resistance genotypes for patient C^a

Sequence no.	Parameter	Result at various times after protease inhibitor failure
		0 or 1 mo	3 mo	23 mo	24 mo	34 mo	37 mo
	Genotype (% total population)b
	Baseline (20R-36I-63P)	100
1	82A		98
2	82A 90M		2
3	54V 71V 82A				13
4	46L 54V 71V 82A			75d	13
5	53L 54V 71V 82A				13
6	54V 71V 82A 90M				1
7	53L 54V 71V 82A 90M					14
8	54V 71V 82A 93L			25	38e	9	6
9	53L 54V 71V 82A 93L				13
10	54V 71V 82A 84V 93L					64d	6
11	54V 71V 82A 90M 93L				9	9	74e
12	46L 54V 71V 82A 90M 93L					4
13	54V 71V 82A 84V 90M 93L						14
	Total no. of clones sequenced (with L90M/without L90M)	0/14	1/3	0/4	8/7	7/8	6/6
	% Total clones with L90M	0	2	0	10	27	88
	Treatmentc		d4T, 3TC, RTV	d4T, 3TC, NFV	EFV, ddI, SQV/RTV	EFV, ddI, SQV/RTV	EFV, d4T-ddI, NFV

^aSee Table 1, footnote a.

^bSee Table 1, footnote b.

^cSee Table 1, footnote c.

^dSee Table 1, footnote d.

^eSee Table 2, footnote e.